UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 27, 2015
SANGUI BIOTECH INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
Colorado
(State or Other Jurisdiction of Incorporation)
000-21271
84-1330732
(Commission File Number) (IRS Employer Identification No.)
Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
(Address of Principal Executive Offices) (Zip Code)
011-49-2302-915-204
(Registrant's Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02.
Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
Resignation of Chief Financial Officer and Director
On October 27, 2015, Sangui Biotech International, Inc. (the “Company”) received the resignation of Joachim Fleing from his positions as Chief Financial Officer and Director effective immediately for personal reasons. There were no disagreementson any matter relating to the Company’s operations, policies or practicesbetween Mr. Fleing and the Company or any officer or director of the Company which led to Mr. Fleing’s resignation.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Sangui Biotech International, Inc.
/s/ Thomas Striepe
Date:
November 3, 2015
____________________________________
By: Thomas Striepe
Its: President